Related by context. All words. (Click for frequent words.) 85 Pivotal Phase 85 Phase III Clinical Trial 85 Meets Primary Endpoint 84 Phase 2b Clinical Trial 83 Completes Patient Enrollment 83 Phase IIb Trial 82 Phase IIb Clinical Trial 82 Patient Enrollment 82 Initiate Phase 82 Pivotal Trial 82 Completes Enrollment 81 Initiates Phase III 81 Clinical Trial Results 80 Initiates Phase II 80 Phase III Trial 80 Investigational Compound 80 Presents Positive 80 Randomized Phase 80 NDA Submission 79 Phase 2a Clinical Trial 79 Receives Orphan Drug Designation 79 Initiates Enrollment 79 Combination REOLYSIN R 79 Pivotal Study 79 Phase III Clinical Trials 79 Dose Ranging Study 78 Study Evaluating 78 Demonstrates Positive 78 JAK Inhibitor 78 Commences Phase 78 Drug Candidate 78 Phase 2b Trial 78 Phase III Trials 78 Initiates Phase 78 Trial Evaluating 78 Initiates Clinical 78 Pivotal Clinical Trial 78 Pafuramidine 78 Prolongs Survival 78 FOLOTYN ® 78 Granted Orphan Drug 78 Patients Treated With 78 FDA Accepts 77 Preclinical Data 77 Oral Fingolimod 77 Phase 2b Study 77 Successfully Completes Phase 77 Novel Oral 77 Pooled Analysis 77 Fast Track Status 77 Adjuvant Treatment 77 Phase III Pivotal 77 Phase 2a Trial 77 Phase 1b Clinical Trial 77 Mylan Receives Approval 77 Severe Sepsis 77 PRN FDA Approves 77 FDA Approvals 77 Initiate Phase III 77 First Patient Enrolled 77 II Clinical Trial 77 Tezampanel 76 Vicriviroc 76 Pivotal Trials 76 Brentuximab Vedotin SGN 76 Achieves Primary Endpoint 76 Expanded Indication 76 SPRYCEL ® 76 Demonstrates Significant 76 Presents Preclinical Data 76 Oral Calcitonin 76 Hsp# Inhibitor 76 Single Dose 76 Hormone Refractory Prostate Cancer 76 Submits NDA 76 Initiates Clinical Trial 76 Aflibercept 76 Randomized Double Blind 75 Previously Treated 75 Metastatic Melanoma 75 Begins Dosing 75 Files IND 75 Sapacitabine 75 Long Term Efficacy 75 Monotherapy 75 Commence Phase 75 Generic Version 75 Advanced Melanoma 75 HDAC Inhibitor 75 Glatiramer Acetate 75 IND Application 75 Phase IIa Clinical Trial 75 Metastatic Colorectal Cancer 75 Complicated Skin 75 Study Showed 75 Investigational Treatment 75 Investigational Drug 75 Well Tolerated 75 Randomized Phase II 75 Placebo Controlled Trial 75 IL# PE#QQR 75 Elagolix 75 Drug Fails 75 Dose Finding 75 IND Filing 74 Relapsing Multiple Sclerosis 74 Presents Preclinical 74 Confirmatory Phase 74 Initiate Phase II 74 Double Blind Placebo 74 Efficacy Trial 74 Receives Positive Opinion 74 Safinamide 74 Golimumab 74 Initiated Phase 74 Improves Survival 74 Files Investigational 74 Lupus Nephritis 74 Pivotal Phase II 74 Patients Treated 74 Zorbtive TM 74 Clinical Trial Evaluating 74 Refractory Hodgkin Lymphoma 74 Patient Enrolment 74 Receives Orphan Drug 74 Lung Cancer Drug 74 Controlled Trial 74 Initiate Clinical Trial 74 Receives Approvable Letter 74 Randomized Double blind 74 Investigational Oral 74 dependent kinase inhibitor 74 Pharmacokinetic Study 74 Cholesterol Lowering Drug 74 Phase Ib II 74 Newly Diagnosed Multiple Myeloma 74 Supplemental Biologics License Application 74 GATTEX TM 74 Present Preclinical Data 74 Teva Provides Update 74 Prospective Randomized 74 Positive Opinion 74 Cutaneous T 74 Adjunctive Therapy 74 Gout Drug 73 Initiates Phase 2b 73 First Patient Dosed 73 Recombinant Human 73 Anti Tumor Activity 73 Renal Cell Carcinoma 73 Intravenous Formulation 73 catheter occlusion 73 Topline Results 73 Prostate Cancer Vaccine 73 Antitumor Activity 73 Patients Receiving 73 Cetrorelix 73 Relapsed Multiple Myeloma 73 Spectrum Pharmaceuticals Announces 73 Shows Promising 73 Fondaparinux 73 Pemetrexed 73 Ambrisentan 73 Receives Fast Track 73 BRIM2 73 Second Pivotal Phase 73 Benign Prostatic Hyperplasia 73 Phase IIIb clinical 73 Diabetic Nephropathy 73 Testosterone Gel 73 Transdermal Patch 73 phase IIb clinical 73 Announces Tentative Approval 73 Investigational Agent 73 Ranolazine 73 Mg Usa 73 Lupus Drug 73 Inhalation Solution 73 methylnaltrexone bromide 73 Pirfenidone 73 Cloretazine ® 73 Capsules CII 73 Statistically Significant 73 REG1 Anticoagulation System 73 Bazedoxifene 73 ORENCIA ® 73 MKC# MT 73 Presents Positive Preclinical 73 Romidepsin 73 Patients Enrolled 73 SinuNase TM 73 pralatrexate injection folate analogue 73 Luveniq 73 Novel Antibiotic 73 Demonstrates Efficacy 73 Multiple Ascending Dose 73 Civacir 73 Demonstrates Potent 73 FDA APPROVES 73 oral prodrug 72 TKB# 72 Protease Inhibitor 72 PDUFA Date 72 Completes Dosing 72 Orphan Status 72 Extended Release 72 Combination Treatment 72 Xcytrin R 72 Pulmonary Arterial Hypertension 72 Improved Survival 72 BRIM3 72 monoclonal antibody conjugated 72 Demonstrate Significant 72 Vascular Disrupting Agent 72 FDA Approvable Letter 72 Earns Milestone Payment 72 BARACLUDE R 72 Dupuytren Contracture 72 lexidronam injection 72 Dose Escalation 72 Survival Benefit 72 fosbretabulin 72 Romiplostim 72 Panzem R NCD 72 Desvenlafaxine Succinate 72 Collaborators Present 72 Kinase Inhibitor 72 interferon gamma 1b 72 Relapsing Remitting Multiple Sclerosis 72 Efficacy Results 72 HCV Protease Inhibitor 72 initiated Phase Ib 72 Psoriasis Drug 72 Lung Cancer Trial 72 Rheumatoid Arthritis Drug 72 Platelet Inhibition 72 Personalized Immunotherapy 72 Phase Ib IIa 72 Stent Restenosis 72 Prophylactic Treatment 72 Peginterferon 72 cetuximab Erbitux R 72 induced macular edema 72 mGluR5 negative 72 Dasatinib 72 Omacetaxine 72 Dalbavancin 72 Amrubicin 72 R Saizen R 72 Ecallantide 72 ALN HPN 72 Bosutinib 72 Randomized Clinical Trial 72 Phase III Pivotal Trial 72 Overactive Bladder 72 Febuxostat 72 Forodesine HCl 72 Zenvia Phase III 72 Improves Outcomes 72 Marketing Authorisation Application 72 acetonide FA 72 severe hypercholesterolemia 72 Parathyroid Hormone 72 Toremifene 72 Inhalation Aerosol 72 pan HDAC inhibitor 72 bone marrow reticulin deposition 72 Pharmacokinetics PK 72 Matrix Phase 2b 72 UPLYSO 72 aripiprazole Abilify 72 Tipranavir 72 Aryplase 72 Acute Attacks 72 Clinical Study 72 ZOLINZA 72 R lenalidomide 72 icatibant 72 Reports Preclinical Data 72 Telbivudine 72 Initiates Clinical Trials 72 Vidaza R 72 VIVITROL ® 72 Tigecycline 72 Vitrasert R 72 Ophena TM 72 Randomized Double Blind Placebo 72 Iloperidone 72 IIa Clinical Trial 72 Mycophenolate Mofetil 72 Phase 2a Study 72 MAGE A3 ASCI 72 evaluating mipomersen 71 PDX pralatrexate 71 Panzem R 71 Novel Inhibitor 71 TO AVOID PREGNANCY WHILE 71 Dose Ranging 71 investigational antiplatelet agent 71 LibiGel ® 71 Diabetic Neuropathy 71 Therapeutic Competitors Companies 71 Controlled Study 71 hoFH 71 Paclitaxel Carboplatin 71 Tesetaxel 71 sapropterin dihydrochloride 71 Pegloticase 71 Shows Efficacy 71 Phase IIIb 71 STELARA TM 71 FDA Clears 71 phase IIa clinical 71 docetaxel Taxotere ® 71 Clinical Trial Data 71 Combination Therapy 71 Plus Ribavirin 71 Osteoporosis Drug 71 Nilotinib 71 Subgroup Analysis 71 Medoxomil 71 Entereg R 71 MKC# 71 Acute Ischemic Stroke 71 including eniluracil ADH 71 Oral Formulation 71 INSPIRE Trial Phase III 71 Preclinical Study 71 TM Drug Eluting 71 Shows Statistically Significant 71 Randomized Study 71 refractory chronic lymphocytic 71 Demonstrates Sustained 71 Patient Outcomes 71 phase IIb trial 71 PEGylated Fab fragment 71 Treated Patients 71 Submits Response 71 Milestone Payment 71 Unfractionated Heparin 71 Soft Tissue Sarcoma 71 Bepreve TM 71 Anti Tumor 71 Is Well Tolerated 71 huC# DM4 71 Tiotropium 71 Friedreich Ataxia FRDA 71 evaluating tivozanib 71 ANDA Filing 71 Demonstrated Significant 71 AVASTIN 71 alfa 2a 71 Study Demonstrates 71 acyclovir Lauriad R 71 Taro Receives 71 Rheumatoid Arthritis Patients 71 Submits Supplemental 71 Sagent Pharmaceuticals Announces 71 Chronic Hepatitis C 71 Tyrosine Kinase Inhibitor 71 Preclinical Models 71 dasatinib Sprycel ® 71 PEGINTRON TM 71 myelodysplastic myeloproliferative diseases 71 Patent Covering 71 EVIZON TM 71 MEK Inhibitor 71 JAK2 Inhibitor 71 MKC# MKC# PP 71 Telithromycin 71 cetuximab Erbitux 71 Schizophrenia Drug 71 Ozarelix 71 Archexin 71 rasagiline tablets 71 2 methoxyestradiol 71 Xelox 71 dual endothelin receptor antagonist 71 Phase Ib Clinical Trial 71 vapreotide acetate 71 Hypertensive Patients 71 Bivalirudin 71 albiglutide 71 phase III isavuconazole 71 Receives Milestone Payment 71 Eluting Stent 71 Fludara ® 71 Plaque Psoriasis 71 Levoleucovorin 71 Interferon beta 1a 71 Pegylated 71 Gemzar ® 71 Tolerability 71 sorafenib tablets 71 receptor tyrosine kinase inhibitor 71 Fungal Infections 71 Ovitrelle R Serostim 71 Tesamorelin 71 Reveals Positive 71 Vaccine Adjuvant 71 ACTEMRA TM 71 Calcium Acetate 71 Rebif ® 71 Anticancer Compound 71 Orally administered 71 selective A2A adenosine receptor 71 Cites Positive 71 Migraine Drug 71 Glufosfamide 71 Rotavirus Vaccine 71 Low Dose 71 Arthritis Drug 71 Lubiprostone 71 Oral Insulin 71 Anturol TM 71 Chronic Myeloid Leukemia 71 Placebo Controlled 71 Peginterferon alfa 2b 70 novel VDA molecule 70 First Patient Treated 70 CYT# potent vascular disrupting 70 Submits Biologics License Application 70 Telik logo TELINTRA 70 Systemic Delivery 70 novel histone deacetylase 70 Release Capsules 70 humanized interleukin 6 70 Peginterferon Alfa 2a 70 Prostate AdenoCarcinoma Treatment 70 APEX PD 70 Resistant Hypertension 70 Xeloda ® 70 adenosine injection 70 Fabry Disease 70 SNT-MC#/idebenone 70 Dyloject TM 70 Phase #b/#a clinical 70 Daptomycin 70 omacetaxine mepesuccinate 70 Insulin Glargine 70 Granulocyte Colony Stimulating Factor 70 Oracea TM 70 Systemic Sclerosis 70 vinorelbine tartrate 70 acute peripheral arterial 70 Maribavir 70 RNAi Therapeutic 70 Cethromycin 70 Commences Phase III 70 forodesine 70 Xanafide 70 Irinotecan 70 Valsartan 70 Neulasta R 70 assessing T DM1 70 ThermoDox R 70 Immunotherapeutic 70 hyaluronidase enzyme 70 AVONEX ® 70 Sevelamer 70 Cannabinor 70 Metastatic Renal Cell Carcinoma 70 Early Relapsing Multiple 70 non nucleoside inhibitor 70 telomerase therapeutic 70 Chronic Hepatitis B 70 Autologous Stem Cell Transplantation 70 Melphalan 70 Phase IIB 70 adalimumab Humira 70 Tolvaptan 70 Gel repository corticotropin injection 70 Generic Versions 70 Raptiva ® 70 Receives FDA Clearance 70 Lamotrigine 70 AAG geldanamycin analog 70 Phase IIA 70 Allergic Rhinitis 70 Advanced Renal Cell 70 HP Acthar Gel repository 70 Intravitreal 70 Bevacizumab 70 dose escalation clinical 70 Microplasmin 70 Cell Lymphoma 70 Antiviral Activity 70 Follicular Lymphoma 70 Tarceva TM 70 Eculizumab 70 TLK# 70 Submits IND 70 Completes Patient Enrolment 70 Randomized Controlled 70 FDA Clearance 70 Treatment Naive Patients 70 Recurrent Glioblastoma 70 Phenoptin 70 orally administered inhibitor 70 Blood Pressure Drug 70 HoFH 70 Alemtuzumab 70 MIVI III 70 Genasense ® oblimersen 70 Aliskiren 70 Hedgehog Pathway Inhibitor 70 pan histone deacetylase 70 Interferon Beta 70 HuMax EGFr 70 Antidepressant Drug 70 oral ridaforolimus 70 Sustained Efficacy 70 Inhaled Insulin 70 cell lymphoma CTCL 70 Cypher Sirolimus 70 Sprycel dasatinib 70 Sangamo BioSciences Announces 70 Catena ® 70 Hepatocellular Carcinoma 70 Metastatic Prostate Cancer 70 Enzyme Replacement Therapy 70 Fluconazole 70 Universal Flu Vaccine 70 virus HCV protease inhibitor 70 Milestone Payments 70 HER2 Positive Breast Cancer 70 Myelodysplastic Syndromes 70 dextromethorphan quinidine 70 Known hypersensitivity 70 lucinactant 70 PEG IFN 70 generation purine nucleoside 70 Vildagliptin 70 Eltrombopag 70 Multicenter Phase 70 Hematological Malignancies 70 rALLy 70 BARACLUDE ® 70 Kamada AAT 70 Clevudine 70 Colorectal Cancer Patients 70 R roscovitine CDK cyclin 70 Randomised 70 inhalation aerosol 70 SNT MC# 70 atypical Hemolytic Uremic Syndrome 70 Fixed Dose 70 Methylnaltrexone 70 Nymox NX 70 Pazopanib 70 sodium thiosulfate STS 70 lintuzumab SGN 70 FDA Okays 70 Temsirolimus 70 Mg Uk 70 Malignant Melanoma 70 Multicenter Randomized 70 Ziprasidone 70 GENERIC SILDENAFIL SOFT Generic 70 Soriatane 70 relapsed MM 70 Naive Patients 70 Betaferon R 70 Cleviprex TM clevidipine 70 Etanercept 70 ara C 70 sunitinib Sutent 70 Azacitidine 70 LUMINATE 70 Confirms Efficacy 70 includes TOLAMBA TM 70 Myelodysplastic Syndrome MDS 70 Ondansetron Injection USP 69 Phase Ib clinical 69 Diabetic Macular Edema 69 Infected Patients 69 Eszopiclone 69 TRANSDUR ® 69 Phase III placebo controlled 69 relapsed refractory multiple myeloma 69 Oral Insulin Capsule 69 guanfacine extended release 69 Raptiva R 69 5 Fluorouracil 69 Ceflatonin R 69 Acute Decompensated Heart Failure 69 Diabetic Neuropathic Pain 69 PANVAC VF 69 Showed Significant 69 Enrolls First 69 Bortezomib 69 miconazole Lauriad ® 69 CD# CEA 69 sorafenib Nexavar 69 PROSTASCINT R 69 candidates Azedra 69 PEG SN# 69 topically administered 69 phase Ib 69 Significantly Improves 69 Fulvestrant 69 Lanthanum Carbonate 69 Myeloma Patients 69 Potent Antiviral Activity 69 Epilepsy Drug 69 Announces Poster Presentations 69 HCV RESPOND 2 69 Generic Version Of 69 Significantly Reduced 69 Tocilizumab 69 Serostim ® 69 Pegylated Liposomal Doxorubicin 69 Adjuvant Therapy 69 Neulasta ® 69 Clinical Study Shows 69 cinacalcet HCl 69 Monoclonal Antibody 69 registrational Phase 69 beta 1a 69 LymphoStat B TM 69 Chronic Lymphocytic Leukemia 69 Camptosar ® 69 Aztreonam Lysine 69 Cholesterol Drug 69 Significantly Improved 69 Darinaparsin 69 Certolizumab 69 Elderly Patients 69 Clolar ® 69 Metabolic Efficiency 69 balsalazide disodium Capsules 69 Paliperidone Palmitate 69 PEGylated anti 69 Hydrochlorothiazide Tablets 69 galiximab 69 antibody MAb 69 6R BH4 69 liver resection surgeries 69 GOUT 69 TELINTRA 69 MYCAMINE 69 Receives Complete Response 69 Replacement Therapy 69 Intervention Effectiveness 69 KRN# 69 Resubmission 69 topical gel formulation 69 investigational humanized monoclonal antibody 69 occlusion PAO 69 Disease Progression 69 BUPHENYL 69 phase IIa 69 Neoadjuvant 69 Immunomedics Announces 69 CCX# B 69 Degarelix 69 Androxal TM 69 metastatic castrate resistant 69 placebo controlled Phase 69 MGd 69 DASISION 69 topically applied SEPA 69 histone deacetylase HDAC inhibitor 69 LEP ETU 69 Nebulized 69 Sanvar R 69 highly purified pasteurized 69 mertansine 69 Pralatrexate 69 INCB# [003] 69 Augment TM 69 Enoxaparin 69 tiapamil 69 diabetic neuropathic pain 69 Epratuzumab 69 Vidaza ® 69 Immunogenicity 69 Demonstrates Potential 69 Paraplatin ® 69 Anticancer Drug 69 SUPPRELIN R LA 69 Zoledronic Acid 69 Synta Announces 69 SUTENT ® 69 Vidaza azacitidine 69 metastatic malignant 69 Treatment Resistant 69 Treatment Naïve 69 Faropenem 69 PHASE III 69 Darusentan 69 ongoing Phase 1b 69 Aloxi ® 69 XYOTAX TM 69 Trandolapril 69 Drug Eluting Stent System 69 cutaneous T 69 Regeneron Pharma 69 TNF Tumor Necrosis Factor 69 Soliris eculizumab 69 Adalimumab 69 Pharmacokinetic 69 budesonide foam 69 Clinical Efficacy 69 octreotide implant 69 TBC# 69 hormone refractory metastatic prostate 69 PROVENGE ® 69 Orally Active 69 prucalopride 69 Phase 1a clinical 69 benzoic acid hyoscyamine sulfate 69 IMPACT DCM 69 targeted radiotherapeutic 69 Adjuvant Chemotherapy 69 Dapagliflozin 69 Malignant Glioma 69 include Phenoptin TM 69 ORAL Sync 69 Interferon beta 1b 69 Bare Metal Stent 69 PEGylated interferon beta 1a 69 documented candidiasis 69 Bucindolol 69 RELOVAIR ™ 69 investigational monoclonal antibody 69 Keppra ® XR 69 EURIDIS 69 herpetic keratitis 69 sitaxsentan 69 Dacogen injection 69 Gets FDA Clearance 69 FUSILEV ® 69 Trodusquemine MSI 69 Delayed Release 69 mGluR5 NAM 69 Testosterone MDTS ® 69 Maleate 69 XL# anticancer compounds 69 Ocrelizumab 69 Interferon Alfa 69 midstage clinical 69 OvaRex ® MAb 69 novel emulsion formulation 69 Fidaxomicin 69 TRANSFORMS 69 Biologic License Application 69 Wafer polifeprosan 69 Refractory Angina 69 Secondary Hyperparathyroidism 69 Tasimelteon 69 ISTODAX ® 69 ALN PCS 69 RAPTIVA 69 docetaxel Taxotere R 69 XIAFLEX ® 69 Kuvan R 69 Capecitabine 69 Targretin capsules 69 arsenic trioxide injection 69 Ereska 69 Active Ulcerative Colitis 69 NEBIDO R 69 Preclinical Efficacy 69 Orphan Drug Status 69 relapsing remitting MS RRMS 69 Indomethacin 69 QLT# 69 Cloretazine 68 Daclizumab 68 Prodrug 68 By JENNIFER LEARN 68 Schizophrenia Treatment 68 BAL# [002] 68 Tanespimycin 68 VISICOL R 68 trastuzumab DM1 T DM1 68 Advanced Prostate Cancer 68 Cinacalcet HCl 68 Palifosfamide 68 GTC recombinant human 68 Kepivance 68 Non Inferiority 68 5 fluorouracil leucovorin 68 samarium Sm 68 Pegylated Interferon 68 Percutaneous Tibial Nerve Stimulation 68 candesartan cilexetil 68 Accelerated Approval 68 multicenter Phase III 68 Sirolimus Eluting 68 RNAi Therapeutics 68 rALLy clinical trial 68 COLAZAL ® 68 Ridaforolimus 68 Tacrolimus 68 PKC# 68 Advaxis Phase 68 T Pred 68 Diffuse Large B 68 Sandostatin R 68 miconazole Lauriad R 68 ORENCIA R 68 BioSante Pharmaceuticals Announces 68 Albuferon TM 68 Agonist MABA program 68 Hemodialysis Patients 68 Gliadel R 68 Telaprevir VX 68 Cimzia ® certolizumab pegol 68 Silodosin 68 insulin glulisine 68 Postmenopausal Osteoporosis 68 oropharyngeal candidiasis OPC 68 Previously Untreated 68 octreotide acetate 68 Proton Pump Inhibitor 68 J Am Coll 68 alefacept 68 GTC recombinant form 68 Partial Onset Seizures 68 HCl Injection 68 Chronic Sinusitis 68 Denufosol 68 Perifosine KRX 68 BENLYSTA ® 68 Ofatumumab 68 oral picoplatin 68 Prostate Cancer Patients 68 Advanced Colorectal Cancer 68 VICTOR E3 68 ospemifene 68 R bisoprolol Euthyrox 68 systemic juvenile idiopathic 68 Data Suggest 68 Pimavanserin 68 Anticancer Activity 68 Lenocta TM 68 ELADUR ™ 68 Drug Eluting Stent 68 Ciclesonide 68 IMPACT IMmunotherapy 68 molecular imaging radiopharmaceutical 68 Postmenopausal Women 68 Iluvien TM 68 Noxafil 68 Deferiprone 68 Metformin HCl 68 blinded randomized placebo controlled 68 erlotinib Tarceva ® 68 Therapeutic Vaccine 68 LymphoStat B belimumab 68 Optimer Pharma 68 Gonal f R 68 TRANSDUR ™ 68 COLAZAL R 68 systemic anaplastic large 68 Interferon Alpha 68 Soliris TM eculizumab 68 Desloratadine 68 phase IIIb 68 refractory gout 68 ZACTIMA 68 #mg BID [001] 68 Acute Myocardial Infarction 68 hyperphenylalaninemia HPA due 68 Treatment Experienced 68 Humanized Anti 68 Advanced Pancreatic Cancer 68 briakinumab 68 Launches Generic Version 68 Small Molecule 68 Receptor Agonist 68 Medullary Thyroid Cancer 68 ACE Inhibitors 68 investigational pan BCR 68 VIVUS Announces 68 diarrhea fatigue asthenia 68 oral nucleoside analogue 68 Cellegesic 68 pharmacokinetic PK study 68 selective modulator 68 Traficet EN 68 IgG1 monoclonal antibody 68 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 68 Relapsed Refractory 68 Naproxcinod 68 StaphVAX R 68 ARIXTRA R 68 achieved CCyR 68 diarrhea predominant irritable 68 familial amyloidotic polyneuropathy FAP 68 biliary tract cancer 68 R memantine HCl 68 ocular formulation 68 liposomal formulation 68 pioglitazone HCl 68 Receive Milestone Payment 68 Marketing Authorisation Application MAA 68 GW# [003] 68 Posaconazole 68 INTEGRILIN R 68 Abiraterone Acetate 68 cromolyn sodium 68 levocetirizine 68 Phase IIb trials 68 FDA Approves 68 Antipsychotic 68 Late Breaker 68 PNP inhibitor 68 Seliciclib CYC# 68 Hypercholesterolemia 68 Diamyd Medical Diamyd 68 Onalta ™ 68 Disease Modifying 68 Novel Mechanism 68 AVAPRO 68 Enzastaurin 68 Kidney Transplant Patients 68 Antitumor 68 RANK Ligand inhibitor 68 recurrent glioblastoma multiforme 68 Acetate Rectal Suppositories 68 reslizumab 68 Clinical Evaluation 68 toenail onychomycosis 68 FDA Approval 68 Announces FDA Clearance 68 oral renin inhibitor 68 Plicera 68 Dual Opioid 68 oral dual endothelin 68 ONCONASE R 68 terlipressin 68 orally inhaled migraine 68 serotonin norepinephrine reuptake inhibitor 68 hypereosinophilic syndrome 68 Unstable Angina 68 ergot derivatives 68 Vandetanib 68 Crofelemer budesonide foam 68 Exherin TM 68 esophageal candidiasis 68 Alocrest 68 Eluting Coronary Stent System 68 LEUKINE 68 Milestone Payment From 68 Nitazoxanide 68 metastatic GIST 68 Initiates Dosing 68 memantine HCl 68 Alfimeprase 68 Gamunex C 68 phase Ib clinical 68 ® lenalidomide 68 Randomized Phase III 68 sarcoma melanoma 68 TNF Blockers 68 PENTASA 68 ENDEAVOR IV 68 alvespimycin 68 ILUVIEN ® 68 fidaxomicin Phase 68 Voreloxin 68 azilsartan medoxomil 68 INCB# [001] 68 novel synthetic PEGylated 68 Decitabine 68 Simulect 68 Moxifloxacin 68 Boceprevir 68 Sunesis Pharma 68 Antiangiogenic 68 MOVIPREP R 68 CHAMPION PCI 68 Entereg TM 68 DAYTRANA TM 68 delivers fluocinolone acetonide FA 68 Multicenter 68 phase IIb 68 ACAPODENE 68 Solazed ™ 68 Teriparatide 68 AFREZZA TM 68 Glycopyrrolate 68 Regenerative Cells 68 ARRY # 68 Onyx Pharmaceuticals Announces 68 GRAS Status 68 PROCTOCORT R 68 Solazed TM 68 crizotinib PF # 68 CIMZIA TM 68 Saizen ® 68 CRMD# 68 BioSante Pharmaceuticals Reports 68 Submits Investigational 68 GALNS 68 Dosage Strengths